dadstimeon Posted April 12, 2007 Share Posted April 12, 2007 Small Cell Lung Cancer http://www.prnewswire.com/cgi-bin/stori ... 353&EDATE= COPENHAGEN, Denmark, April 12 /PRNewswire-FirstCall/ -- Genmab A/S (CSE: GEN) announced today it has initiated a Phase II study of HuMax-EGFr (zalutumumab) in combination with chemo-radiation to treat non small cell lung cancer (NSCLC). The study will include a maximum of 270 previously untreated patients with advanced NSCLC. "We are excited to expand the HuMax-EGFr program into this new indication and hope that it may some day prove to be an effective treatment for lung cancer patients," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. About the trial This open label study consists of two parts. Part 1 will include at least 24 patients divided into two sequential treatment groups. Patients in Group A will receive 2 cycles of induction chemotherapy in combination with weekly fixed doses of 8 mg/kg of HuMax-EGFr followed by 7 weekly 8 mg/kg doses of HuMax-EGFr in combination with radiotherapy. Pending satisfactory evaluation of safety data from Group A, patients in Group B will receive 2 cycles of induction chemotherapy in combination with HuMax-EGFr at individually titrated doses up to 16 mg/kg, based on the degree of skin rash the patient develops. This will be followed by 7 weekly doses of HuMax-EGFr in combination with chemo-radiation. Safety data from Part 1 of the trial will be evaluated to determine if it is safe to begin Part 2. There will be two treatment groups in Part 2 of the study. Patients will receive either 2 cycles of induction chemotherapy in combination with weekly doses of up to 16 mg/kg of HuMax-EGFr followed by 7 weekly doses of HuMax-EGFr in combination with chemo-radiation or 2 cycles of induction chemotherapy followed by chemo-radiation alone. In both parts of the study, patients will be evaluated every 3 months until disease progression and every 4 weeks thereafter until death in accordance with the general methodology of trials in cancer patients. The objective of the study is to evaluate the safety and efficacy of HuMax-EGFr in combination with chemo-radiation versus chemo-radiation alone in the treatment of advanced NSCLC. The primary endpoint of the study is progression free survival from randomization until disease progression or death. About Non Small Cell Lung Cancer NSCLC is the leading cause of cancer deaths in both men and women, with approximately 172,000 patients being diagnosed annually in the US. Almost 25% of newly diagnosed patients will have advanced (stage IIIA or IIIB) disease for which effective treatment options are few. About Genmab A/S Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb® platform for the rapid creation and development of human antibodies to virtually any disease target. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. For more information about Genmab, visit http://www.genmab.com . This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law. Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD4®; HuMax- EGFr; HuMax-Inflam; HuMax-CD20; HuMax-TAC; HuMax-HepC, HuMax-CD38; HuMax-ZP3; and UniBody are all trademarks of Genmab A/S. UltiMAb® is a trademark of Medarex, Inc. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.